替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床研究 : = Clinical trial of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome
目的观察替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床疗效及安全性。方法将70例艾滋病患者随机分为对照组和试验组,每组35例。对照组予以齐多夫定每次0.3 g,bid,口服,qd,口服+拉米夫定每次0.3 g,qd,口服+依非韦伦每次600 mg,qd,口服;试验组予以替诺福韦每次300mg,qd,口服+拉米夫定每次0.3 g,qd,口服+洛匹那韦利托那韦每次500 mg,bid,口服。2组患者均治疗1年。比较2组患者的CD4+T淋巴细胞、生活质量评分和药物不良反应的发生情况。结果治疗后,试验组和对照组的CD4~+分别为(42.43±4.60)%和(35.99±3.84)%,生活质量总评分分别为(88.02±8.81)和(76.45±7.54)分,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有腹泻、恶心和呕吐,对照组的药物不良反应主要有头晕。试验组和对照组的总药物不良反应发生率分别为11.43%和17.14%,差异无统计学意义(P>0.05)。结论替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床疗效确切,且不增加药物不良反应的发生率。.
Objective To observe the clinical efficacy and safety of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome( AIDS). Methods A total of 70 patients with AIDS were randomly divided into control and treatment groups with 35 cases per group. Control group was given zidovudine 0. 3 g per time,bid,orally + lamivudine0. 3 g per time,qd,orally + efavirenz 600 mg per time,qd,orally.Treatment group received tenofovir 300 mg per time,qd,orally + lamivudine 0. 3 g per time,qd,orally + lopinavir and ritonavir 500 mg per time,bid,orally. Two groups were treated for 1 year. The CD4~+T lymphocytes,quality of life score and adverse drug reactions were compared between two groups. Results After treatment,the main indexes of treatment and control groups were compared: CD4+were( 42. 43 ± 4. 60) %and( 35. 99 ± 3. 84) %,total quality of life scores were( 88. 02 ± 8. 81)and( 76. 45 ± 7. 54),the differences were statistically significant( all P < 0. 05). The adverse drug reactions of treatment group were diarrhea,nausea and vomiting,which in control group were dizziness. The total incidences of adverse drug reactions in treatment and control groups were11. 43% and 17. 14% without significant difference( P > 0. 05). Conclusion Tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets have a definitive clinical efficacy in the treatment of AIDS,without increasing the incidence of adverse drug reactions..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018-08-17 2018 |
|---|---|
| Erschienen: |
2018-08-17 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2018 |
|---|---|
| Enthalten in: |
Zhong guo lin chuang yao li xue za zhi - (2018), 15 vom: 17. Aug., Seite 1822-1824 Original Letters: Enthalten in 中国临床药理学杂志 (DE-600)2991262-3 (DE-600)2991262-3 北京市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Clinical trial of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome |
|---|
| Beteiligte Personen: |
林永年 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:LIN Yong-nian;HE Xiu-hua;GAO Yi-peng;CHEN Su-mei;LIU Jiang-fu;LIN Meng-xin;QIU Yan-yan;GUO Ru-yi;Department of Infectious Diseases,The First Hospital of Quanzhou City;Department of Medical Services,The Infectious Disease Control Hospital of Quanzhou City |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ603535518 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ603535518 | ||
| 003 | DE-627 | ||
| 005 | 20230119061452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221230s2018 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ603535518 | ||
| 035 | |a (SBB-XA)CAJ_GLYZ201815025 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R512.91 |2 clc | ||
| 100 | 0 | |a 林永年 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床研究 |b = Clinical trial of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome |
| 246 | 3 | 1 | |a Clinical trial of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome |
| 264 | 1 | |c 2018-08-17 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:LIN Yong-nian;HE Xiu-hua;GAO Yi-peng;CHEN Su-mei;LIU Jiang-fu;LIN Meng-xin;QIU Yan-yan;GUO Ru-yi;Department of Infectious Diseases,The First Hospital of Quanzhou City;Department of Medical Services,The Infectious Disease Control Hospital of Quanzhou City | ||
| 520 | |a 目的观察替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床疗效及安全性。方法将70例艾滋病患者随机分为对照组和试验组,每组35例。对照组予以齐多夫定每次0.3 g,bid,口服,qd,口服+拉米夫定每次0.3 g,qd,口服+依非韦伦每次600 mg,qd,口服;试验组予以替诺福韦每次300mg,qd,口服+拉米夫定每次0.3 g,qd,口服+洛匹那韦利托那韦每次500 mg,bid,口服。2组患者均治疗1年。比较2组患者的CD4+T淋巴细胞、生活质量评分和药物不良反应的发生情况。结果治疗后,试验组和对照组的CD4~+分别为(42.43±4.60)%和(35.99±3.84)%,生活质量总评分分别为(88.02±8.81)和(76.45±7.54)分,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有腹泻、恶心和呕吐,对照组的药物不良反应主要有头晕。试验组和对照组的总药物不良反应发生率分别为11.43%和17.14%,差异无统计学意义(P>0.05)。结论替诺福韦片联合拉米夫定片和洛匹那韦利托那韦片治疗艾滋病的临床疗效确切,且不增加药物不良反应的发生率。 | ||
| 520 | |a Objective To observe the clinical efficacy and safety of tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets in the treatment of acquired immunodeficiency syndrome( AIDS). Methods A total of 70 patients with AIDS were randomly divided into control and treatment groups with 35 cases per group. Control group was given zidovudine 0. 3 g per time,bid,orally + lamivudine0. 3 g per time,qd,orally + efavirenz 600 mg per time,qd,orally.Treatment group received tenofovir 300 mg per time,qd,orally + lamivudine 0. 3 g per time,qd,orally + lopinavir and ritonavir 500 mg per time,bid,orally. Two groups were treated for 1 year. The CD4~+T lymphocytes,quality of life score and adverse drug reactions were compared between two groups. Results After treatment,the main indexes of treatment and control groups were compared: CD4+were( 42. 43 ± 4. 60) %and( 35. 99 ± 3. 84) %,total quality of life scores were( 88. 02 ± 8. 81)and( 76. 45 ± 7. 54),the differences were statistically significant( all P < 0. 05). The adverse drug reactions of treatment group were diarrhea,nausea and vomiting,which in control group were dizziness. The total incidences of adverse drug reactions in treatment and control groups were11. 43% and 17. 14% without significant difference( P > 0. 05). Conclusion Tenofovir tablets combined with lamivudine tablets and lopinavir and ritonavir tablets have a definitive clinical efficacy in the treatment of AIDS,without increasing the incidence of adverse drug reactions. | ||
| 610 | 2 | 4 | |a 泉州市第一医院感染科 |
| 610 | 2 | 4 | |a 泉州市传染病防治医院医务科 |
| 650 | 4 | |a 传染病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Infectious Disease | |
| 650 | 4 | |a Endocrine and Systemic Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 替诺福韦片 | |
| 650 | 4 | |a 拉米夫定片 | |
| 650 | 4 | |a 洛匹那韦利托那韦片 | |
| 650 | 4 | |a 艾滋病 | |
| 650 | 4 | |a 安全性 | |
| 650 | 4 | |a tenofovir tablet | |
| 650 | 4 | |a lamivudine tablet | |
| 650 | 4 | |a lopinavir and ritonavir tablet | |
| 650 | 4 | |a acquired immune deficiency syndrome | |
| 650 | 4 | |a safety | |
| 700 | 0 | |a 何秀华 |4 oth | |
| 700 | 0 | |a 高艺鹏 |4 oth | |
| 700 | 0 | |a 陈素梅 |4 oth | |
| 700 | 0 | |a 刘江福 |4 oth | |
| 700 | 0 | |a 林孟新 |4 oth | |
| 700 | 0 | |a 邱燕燕 |4 oth | |
| 700 | 0 | |a 郭如意 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Zhong guo lin chuang yao li xue za zhi |d Bei jing shi, 1985 |g (2018), 15 vom: 17. Aug., Seite 1822-1824 |h Online-Ressource |w (DE-627)CAJ142435430 |w (DE-600)2991262-3 |7 nnns |
| 773 | 1 | 8 | |g year:2018 |g number:15 |g day:17 |g month:08 |g pages:1822-1824 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201815025 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201815025 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 中国临床药理学杂志 |d 北京市 |h Online-Ressource |w (DE-627)CAJ142435430 |w (DE-600)2991262-3 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2018 |e 15 |b 17 |c 08 |h 1822-1824 |
| 951 | |a AR | ||
| 952 | |j 2018 |e 15 |b 17 |c 08 |h 1822-1824 | ||
| 980 | |2 11 |1 01 |x 0001 |b 623037068 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 30-12-22 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201815025 | ||